Cytologically distinct acute leukemia in sibs exposed to the same leukemogen.
Colovic
M
M
Institute of Haematology, Clinical Center of Serbia, Koste Todorovica 2, 11000 Belgrade, Yugoslavia.
Jankovic
G
G
Suvajdzic
N
N
Kraguljac
N
N
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001554:Benzene / Q000633:toxicity*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017809:Fatal Outcome; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D007764:Lacquer / Q000633:toxicity*; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000188:drug therapy / Q000235:genetics; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000139:chemically induced* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009784:Occupational Diseases / Q000139:chemically induced*; D016273:Occupational Exposure; D035781:Siblings; D012907:Smoking; D013256:Steroids / Q000008:administration & dosage; D014186:Transportation; D001335:Vehicle Emissions / Q000633:toxicity*; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D006680:HLA Antigens; D013256:Steroids; D001335:Vehicle Emissions; D014750:Vincristine; D003520:Cyclophosphamide; D001554:Benzene; D008727:Methotrexate; D003630:Daunorubicin